Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis
Phase 1 · Testing ATTO-1091 · Sites not listed yet · Attovia Therapeutics Inc
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
This study is testing ATTO-1091 (a drug) as a possible treatment. Condition(s) listed: Ulcerative Colitis (UC).
Participants are assigned to groups by chance (randomized).
Some participants receive a placebo or sham for comparison.
It is blinded: participants and the study team do not know who receives what.
Phase 1 studies are early tests in a small group of people, mainly checking safety and dosing.
Who can join
- Ages 18 to 65
- Any sex
- Healthy volunteers accepted
Some of the main requirements, copied from the record:
- Parts 1\&2 (Healthy Volunteers) Key Inclusion Criteria:
- Any sex or gender who is 18 to 60 years old, inclusive, at Screening.
- Body weight of 45 to 125 kg, inclusive, and body mass index (BMI) between 18.5 and 35 kg/m2.
Plus 48 more requirement(s). Only the trial team can confirm whether you qualify.
What's involved
- About 96 participants are expected to take part.
- Start date: 2026-12-14 (planned).
- Main results expected around 2028-07-15 (estimate from the record).
- No study sites are listed yet. Check the official record for contact details.
Main thing being measured
- Incidence of AEs (0-169 Days for SAD; 0-204 Days for MAD in HV; 0-141 Days for MAD in UC)
In the researchers’ words
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics (PK) of ATTO-1091 in healthy adults and patients with ulcerative colitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-1091?
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Not yet recruiting |
|---|---|
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis (UC) |
| Lead sponsor | Attovia Therapeutics Inc |
| Enrollment | 96 (estimated) |
| Start date | 2026-12-14 |
| Primary completion (est.) | 2028-07-15 |
| First posted | 2026-09-15 |
| Last updated | 2026-09-15 |
| Official title | A Phase 1, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis |
| ClinicalTrials.gov ID | NCT07819799 |
Interventions
- ATTO-1091 (Drug)
ATTO-1091 - Placebo (Drug)
Placebo preparation to match ATTO-1091 dose
Full eligibility criteria (from the record)
Parts 1\&2 (Healthy Volunteers) Key Inclusion Criteria: * Any sex or gender who is 18 to 60 years old, inclusive, at Screening. * Body weight of 45 to 125 kg, inclusive, and body mass index (BMI) between 18.5 and 35 kg/m2. * Considered in good general health based on medical history, physical exam, 12-lead ECG, screening clinical laboratory findings, and vital signs. * Meets contraception requirements * Negative pregnancy test for participants of childbearing potential. Part 3 (Participants with Ulcerative Colitis) Key Inclusion Criteria: * Any sex or gender who is 18 to 80 years old * Body weight of 45 to 125 kg and BMI between 17.0 and 40.0 kg/m2 * UC diagnosis confirmed by endoscopy and histology ≥3 months prior to Screening * Moderately to severely active UC as defined by Modified Mayo Clinic Score (stool frequency, rectal bleeding, endoscopy) 5 to 9 inclusive, with Mayo endoscopic subscore ≥2 as confirmed by the central reader during Screening * Rectal bleeding subscore ≥1 and stool frequency subscore ≥1 at Screening. * Naïve to treatment with advanced therapies or has had an inadequate response, loss of response, or intolerance to no more than 3 drugs in 2 classes of the following: * Tumor necrosis factor (TNF-α) antagonists * Interleukin IL-12/IL-23 antagonists * Integrin inhibitors * JAK antagonists * S1P receptor agonists * Novel class with biologic-like activity (e.g. TL1A antagonists) * Meets washout criteria for prior UC therapies as specified in the protocol. * Negative pregnancy test for participants of childbearing potential Parts 1\&2 (Healthy Volunteers) Key Exclusion Criteria * Any clinically significant underlying illness * History of malignancy within 5 years of Screening * History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study * History of uncontrolled asthma requiring systemic corticosteroids or hospitalization for asthma within 6 months prior to Day 1 * History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients * Active hepatitis B virus (HBV) or hepatitis C virus (HCV) or is positive for HIV * Active or latent tuberculosis infection * Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent to approximately 40 mg nicotine) per day * History of drug or alcohol abuse * Laboratory values outside of the normal range considered clinically significant by the investigator Part 3 (Participants with Ulcerative Colitis) Key Exclusion Criteria: * Any clinically significant underlying illness * History of malignancy within 5 years of Screening * History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study * History of uncontrolled asthma requiring systemic corticosteroids or hospitalization for asthma within 6 months prior to Day 1 * History of known primary immunodeficiency or is considered immunocompromised * Has been treated for a parasitic infection in the past 6 months * Participant has active HBV or HCV or is positive for HIV * Participant has active or latent TB * Stool positive for Clostridioides difficile toxin at Screening * Concomitant primary sclerosing cholangitis. * History of active major depressive episode or suicidal ideation * History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients * Diagnosis of non-UC or confounding GI conditions including Crohn's disease, indeterminate colitis, microscopic colitis, ischemic or radiation colitis. * Disease limited to isolated ulcerative proctitis (<15 cm). * Unresected colonic dysplasia or unresected adenomatous colonic polyps, fulminant colitis, toxic megacolon, bowel perforation, current colonic strictures, fistulae, stoma, ileostomy, colostomy, abdominal abscess, or anticipated need for colectomy during the study. * History of extensive colonic resection * History of drug or alcohol abuse * Laboratory values outside of the normal range considered clinically significant by the investigator
Locations (0)
No sites listed yet. The official record has contact information.
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.